{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:10:55Z","timestamp":1761487855743,"version":"3.33.0"},"reference-count":14,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,6,7]],"date-time":"2007-06-07T00:00:00Z","timestamp":1181174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2007,7]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>In 2003, the World Health Organization (WHO) and Joint United Nations Programme on HIV\/AIDS (UNAIDS) introduced the \u20183 by 5 Initiative\u2019 to treat 3 million individuals by the end of 2005. This study evaluates the time to treatment termination, viral load suppression, and detection of drug resistance among antiretroviral\u2010na\u00efve individuals initiating stavudine\/lamivudine\/nevirapine (d4T\/3TC\/NVP) in British Columbia, Canada, to provide a context for future programme planning.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Primary outcome was time to treatment termination. Secondary outcome was time to viral suppression. Accumulation of drug resistance mutations was followed systematically in the first 145 individuals over 30 months. Cox proportional hazard regression identified factors associated with termination and suppression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>312 antiretroviral\u2010na\u00efve individuals initiated d4T\/3TC\/NVP between August 1996 and September 2003. Median follow\u2010up time was 26.5 months (interquartile range [IQR] 6.8\u201346.5). At a median of 12.4 months (IQR 4.3\u201333.3), 132 (42.3%) patients switched treatment, 53 (17.0%) stopped therapy and 26 (8.3%) died. Of 308 subjects with baseline viral load &gt;500\u2003copies\/mL, 223 (72.4%) suppressed to \u2264500\u2003copies\/mL at a median of 2.0 months. Among 145 (46.5%) individuals followed longitudinally, resistance mutations to NNRTI, 3TC, or other NRTI were detected in 11 (7.6%), six (4.1%) and four (2.8%) individuals after 12 months of therapy; and in 23 (15.9%), 17 (12.0%), and six (4.1%) individuals after 30 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The population requiring second\u2010line treatment was 30% at 12 months and 40% at 24 months; 20% had detectable drug resistance mutations by 30 months. While these results are from a Western setting, they illustrate the need to consider second\u2010 and third\u2010line approaches as antiretroviral treatment scale\u2010up continues in the developing world.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2007.00463.x","type":"journal-article","created":{"date-parts":[[2007,6,7]],"date-time":"2007-06-07T07:34:48Z","timestamp":1181201688000},"page":"267-270","source":"Crossref","is-referenced-by-count":8,"title":["Performance of a World Health Organization first\u2010line regimen (stavudine\/lamivudine\/nevirapine) in antiretroviral\u2010na\u00efve individuals in a Western setting"],"prefix":"10.1111","volume":"8","author":[{"given":"LWY","family":"Tam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RS","family":"Hogg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Yip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JSG","family":"Montaner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PR","family":"Harrigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CJ","family":"Brumme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,6,7]]},"reference":[{"unstructured":"World Health Organization.About the 3 by 5 Initiative.http:\/\/www.who.int\/3by5\/about\/initiative\/en\/index.html2005.","key":"e_1_2_6_2_2"},{"volume-title":"Scaling up Antiretroviral Therapy in Resource\u2010Limited Settings. Treatment Guidelines for a Public Health Approach","year":"2004","author":"World Health Organization","key":"e_1_2_6_3_2"},{"doi-asserted-by":"publisher","key":"e_1_2_6_4_2","DOI":"10.1001\/jama.286.20.2568"},{"doi-asserted-by":"publisher","key":"e_1_2_6_5_2","DOI":"10.1086\/427192"},{"key":"e_1_2_6_6_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables (with discussion)","volume":"34","author":"Cox DR.","year":"1972","journal-title":"J R Stat Series Soc B"},{"key":"e_1_2_6_7_2","first-page":"65","article-title":"Management of HIV\u20101 infection with a combination of nevirapine, stavudine, and lamivudine","volume":"40","author":"Idigbe EO","year":"2005","journal-title":"a preliminary report on the Nigerian antiretroviral program"},{"key":"e_1_2_6_8_2","first-page":"760","article-title":"Safety and efficacy of a simplified fixed\u2010dose combination of stavudine, lamivudine and nevirapine (GPO\u2010VIR) for the treatment of advanced HIV\u2010infected patients","volume":"87","author":"Anekthananon T","year":"2004","journal-title":"a 24-week study"},{"doi-asserted-by":"publisher","key":"e_1_2_6_9_2","DOI":"10.1007\/s10461-005-9009-y"},{"doi-asserted-by":"publisher","key":"e_1_2_6_10_2","DOI":"10.1089\/apc.2005.19.326"},{"key":"e_1_2_6_11_2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/135965350000500402","article-title":"Effectiveness and pitfalls of initial highly active antiretroviral therapy in HIV\u2010infected patients in routine clinical practice","volume":"5","author":"Moreno A","year":"2000","journal-title":"Antivir Ther"},{"key":"e_1_2_6_12_2","first-page":"289","article-title":"Why are baseline HIV RNA levels 100,000 copies\/mL or greater associated with mortality after the initiation of antiretroviral therapy?","volume":"38","author":"Wood E","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_6_13_2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1177\/135965350300800601","article-title":"Age, adherence and injection drug use predict virological suppression among men and women enrolled in a population\u2010based antiretroviral drug treatment programme","volume":"8","author":"O'Connell JM","year":"2003","journal-title":"Antivir Ther"},{"doi-asserted-by":"publisher","key":"e_1_2_6_14_2","DOI":"10.1086\/378703"},{"unstructured":"World Heath Organization.Coverage and Need for Antiretroviral Treatment.http:\/\/www.who.int\/hiv\/facts\/cov0605\/en\/index.html2005.","key":"e_1_2_6_15_2"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2007.00463.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2007.00463.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T01:29:54Z","timestamp":1737077394000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2007.00463.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,7]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["10.1111\/j.1468-1293.2007.00463.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2007.00463.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"type":"print","value":"1464-2662"},{"type":"electronic","value":"1468-1293"}],"subject":[],"published":{"date-parts":[[2007,6,7]]}}}